Nanostructured Ultrafiltration Membranes for Biological Applications

用于生物应用的纳米结构超滤膜

• 批准号: 8001563
• 负责人: Oleg G. Polyakov
• 金额: $ 42.78万
• 依托单位: SYNKERA TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-05-15 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8001563
• 关键词: Address; Aluminum Oxide; Architecture; Area; Biochemical; Biological; Biological Sciences; Biomanufacturing; Biomedical Research; Blood; Caliber; Cardiac Surgery procedures; Caring; Cell Culture Techniques; Cells; Ceramics; Chemistry; Colorado; Communities; Complement; Complex; Custom; Development; Diagnostic; End stage renal failure; Ensure; Evaluation; Family; Feedback; Fractionation; Glucose; Goals; Government; Health Benefit; Healthcare; Hemodialysis; Investments; Laboratories; Laboratory Study; Letters; Manufacturer Name; Marketing; Medical; Medical Research; Membrane; Mission; Molds; Molecular Sieve Chromatography; Molecular Weight; National Institute of General Medical Sciences; Norway; Nucleic Acids; Patients; Performance; Persons; Phase; Polymers; Polysaccharides; Process; Proteins; Readiness; Reproducibility; Research Personnel; Secure; Small Business Innovation Research Grant; Staging; Structure; Surface; Switzerland; Syringes; Technology; Time; Tube; Ultrafiltration; Universities; Virus; Water; Water Purification; Width; Work; analog; base; bioimaging; commercialization; cost; falls; industry partner; interest; macromolecule; meetings; nanoscale; nanostructured; novel; product development; prototype; public health relevance; research and development

DESCRIPTION (provided by applicant): This multi-phase SBIR project targets a significant problem within the mission of the National Institute of General Medical Sciences: rapid size-based purification and separation of macromolecules, including proteins, nucleic acids and polysaccharides. The main objective is to develop novel ultrafiltration membranes with unprecedented sharp and controllable molecular-weight cut-off (MWCO) and reduced fouling. Such membranes are needed to fully realize the potential benefits of ultrafiltration (UF) and thereby address various pressing needs in biochemical and medical research, medical care, bioanalysis and biomanufacturing. Synkera aims to addresses this challenge by developing and commercializing membranes made from self-organized nanoporous ceramic with practically monodisperse nanometer-scale pores. At the core of this approach, which was proven feasible in Phase I, is Synkera's unprecedented ability to precisely tune the membrane pore diameter to any value in the 0.5-150 nm range. All the key Phase I objectives have been met or exceeded. For the first time, Synkera fabricated prototypes of such membranes and demonstrated their superior performance in comparison with commercial membranes. A clear breakthrough opportunity is now open to develop a whole new family of UF membranes for a variety of applications with enormous market potential and technical, economical, and health benefits to the end users, consumers and patients. Not only do the new membranes offer a performance improvement for established UF uses, but the advanced architecture and unrivaled control of the structure of Synkera's membranes also potentially enable new breakthrough applications such as fractionation of complex macromolecule mixtures. To fully explore the potential of this technology, Synkera established collaborative R&D with several academic and industrial partners. The near-term products based on the proposed technology include planar UF filters that outperform currently available membranes, as well as application-specific membranes (e.g., for protein separation) and bioanalysis substrates (e.g., for glucose sensing). In partnership with OEM manufacturers of biomedical consumables, we will also develop and commercialize centrifuge, syringe and in-line filters, filter cartridges, multiwell-plate inserts, and UF modules. The main objective of Phase II is now to perform a systematic development of the membrane technology to meet the requirements of different applications, and advance it to a readiness level that enables inexpensive yet high-performance membranes and derivative products. PUBLIC HEALTH RELEVANCE: The project addresses a significant problem in biomedical research and medical care: rapid size-based purification and separation of macromolecules, including proteins, nucleic acids and polysaccharides. The development of novel advanced ultrafiltration membranes with unprecedented sharp and controllable molecular-weight cut-off and reduced fouling is proposed. The proposed technology will enable a novel family of high-performance membranes for use in biochemical analysis, laboratory studies, and, potentially, in hemodialysis for treatment of end-stage renal failure and in open heart surgery for blood oxygenation.

描述（由申请人提供）：这个多相SBIR项目针对美国国家一般医学科学研究所的任务中的一个重大问题：基于尺寸的快速纯化和大分子的分离，包括蛋白质，核酸，核酸和多糖。主要目的是开发新型的超滤膜，并具有前所未有的尖锐和可控的分子量截止（MWCO）并减少结垢。需要这样的膜以充分实现超滤（UF）的潜在好处，从而满足生化和医学研究，医疗，生物分析和生物制造的各种紧迫需求。 Synkera的目标是通过开发和商业化由自组织的纳米多孔陶瓷制成的膜，实际上是单分散的纳米尺度毛孔来应对这一挑战。这种方法的核心是在第一阶段被证明是可行的，是Synkera精确调整膜孔直径为0.5-150 nm范围内任何值的前所未有的能力。所有关键的I阶段目标均已满足或超过。 Synkera首次制造了这种膜的原型，并与商业膜相比表现出了出色的性能。现在，一个明显的突破机会开放，可以开发一个全新的UF膜家庭，用于为最终用户，消费者和患者提供巨大市场潜力以及技术，经济和健康益处的各种应用。新膜不仅为已建立的UF用途提供了性能的改进，而且对Synkera膜结构的高级体系结构和无与伦比的控制也有可能实现新的突破性应用，例如复杂的大分子混合物的分馏。为了充分探索这项技术的潜力，Synkera与几个学术和工业合作伙伴建立了合作研发。基于提议的技术的近期产品包括平面UF过滤器，这些过滤器均优于当前可用的膜以及特定于应用特定的膜（例如，用于蛋白质分离）和生物分析底物（例如，用于葡萄糖感应）。与生物医学消耗品的OEM制造商合作，我们还将开发和商业化离心机，注射器和在线过滤器，滤镜盒，多层板插入物和UF模块。第二阶段的主要目的是进行膜技术的系统开发，以满足不同应用的要求，并将其提高到准备水平，使其能够廉价而又高性能的膜和衍生产品。 公共卫生相关性：该项目解决了生物医学研究和医疗护理中的一个重大问题：基于大小的纯化和大分子的分离，包括蛋白质，核酸和多糖。提出了新型高级超滤膜的发展，并提出了前所未有的尖锐和可控的分子量截止和减少的结垢。提出的技术将使一个新型的高性能膜家族用于生化分析，实验室研究，并有可能在血液透析中用于治疗终末期肾衰竭和开放性心脏手术的血液氧合。